Protagonist Therapeutics (PTGX) Common Equity (2015 - 2026)

Protagonist Therapeutics has disclosed Common Equity across 12 years of filings, most recently posting $655.5 million for Q1 2026.

• Common Equity for Q1 2026 came in at $655.5 million, down 4.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $655.5 million (down 4.87% YoY), and the FY2025 annual result was $614.7 million, down 8.97% from the prior year.
• Common Equity came in at $655.5 million for Q1 2026 at Protagonist Therapeutics, up from $614.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $689.1 million in Q1 2025 to a low of $215.6 million in Q4 2022.
• The 5-year median for Common Equity is $531.9 million (2024), against an average of $456.5 million.
• Across the five-year window, Common Equity retreated 28.37% in 2023 and soared 159.26% in 2024, its largest moves.
• Protagonist Therapeutics' Common Equity stood at $215.6 million in 2022, then soared by 56.15% to $336.7 million in 2023, then jumped by 100.58% to $675.3 million in 2024, then dropped by 8.97% to $614.7 million in 2025, then climbed by 6.63% to $655.5 million in 2026.
• The last three Common Equity figures came in at $655.5 million (Q1 2026), $614.7 million (Q4 2025), and $645.4 million (Q3 2025), per Business Quant data.